Longevity Statistics: The Healthspan Gap and a $67 Billion Market (2026)

"Longevity" has moved from fringe biohacking to a fast-growing global market. But the number that matters most isn't market size — it's the widening gap between how long people live and how long they live well. Here's where both stand in 2026.

The healthspan–lifespan gap

A Mayo Clinic analysis of 183 countries, published in JAMA Network Open in 2024, found the global gap between total lifespan and healthy, disease-free years reached 9.6 years in 2019, up from 8.5 years in 2000 — a 13% increase in two decades. The United States posted the largest gap in the world: 12.4 years, meaning the average American now spends more than a decade of life burdened by disease or disability. The gap is wider for women, who average 2.4 more years of poor health than men globally.

Years lived in poor health (healthspan-lifespan gap), 2019. Source: Garmany & Terzic, JAMA Network Open, 2024.

The driver is chronic disease, not accidents or acute illness. Roughly 46% of Americans aged 75 and older now live with at least one disability, according to the U.S. Census Bureau. Lifespan keeps rising; healthy years are not keeping pace.

The longevity market by the numbers

Capital is following the problem. The global longevity market was valued at about $27.6 billion in 2025 and is projected to reach $67 billion by 2035, a compound annual growth rate near 9.4%. The broader anti-aging market — which includes aesthetics and skincare — is larger still, around $78 billion in 2025.

Metric	Figure
Global longevity market (2025)	$27.6B
Global longevity market (2035, projected)	$67.0B
CAGR (2026–2035)	~9.4%
Broader anti-aging market (2025)	~$78B
Longevity startup funding (2024)	$8.49B / 331 deals
NAD+ products market (2024)	$3.45B
U.S. longevity clinics (est.)	~800

Where consumers are spending

Spending skews heavily toward what people can buy directly. Supplements account for roughly 42% of longevity revenue, and direct-to-consumer channels make up about 32% of the market. NAD+ precursors alone — NMN, NR and related compounds — represented a $3.45 billion market in 2024. On the services side, an estimated 800 longevity-focused clinics now operate in the United States, offering biological-age testing, biomarker panels and preventive protocols that were unavailable to consumers a decade ago.

The throughline

Lifespan is rising while healthspan stalls, and the market is pivoting from treating disease late to measuring and preventing it early — biological-age testing, biomarker tracking, and quarterly monitoring. That shift toward proactive, measurable health is the entire premise behind closing the 12.4-year gap. See what OneTwenty measures.

Sources: Garmany A, Terzic A. "Global Healthspan-Lifespan Gaps Among 183 WHO Member States." JAMA Network Open, 2024. SNS Insider, Longevity Market Report, 2026. Custom Market Insights / Precedence Research, Anti-Aging Market, 2026. Grand View Research, NAD+ market data, 2024. Industry funding data, 2024. Figures are the most recent available and should be re-verified before each annual update.

Last reviewed June 2026 · OneTwenty Research